$0.30
1.57% yesterday
Nasdaq, Nov 15, 10:18 pm CET
ISIN
US92731L1061
Symbol
VINC
Reports
Quarter | Annual
Index
NASDAQ Composite
Sector
Health
Industry
Pharmaceuticals

Vincerx Pharma Inc Stock News

Neutral
GlobeNewsWire
●
about one month ago
Vincerx Reports Positive Initial Clinical Data from Ongoing VIP943 Phase 1 Dose-Escalation Study and Provides Pipeline and Corporate Updates
VIP943 demonstrates promising safety and tolerability and achieves two complete responses to date in Phase 1 dose-escalation study, reinforcing the program's potential and validating the VersAptx™ Platform technology
Neutral
GlobeNewsWire
●
3 months ago
Vincerx Pharma Reports Second Quarter 2024 Financial Results
Vincerx continues to enroll its Phase 1 studies of antibody-drug conjugate (ADC) VIP943, with data expected by the end of Q4 2024, and small molecule drug-conjugate (SMDC) VIP236, with data expected at the end of Q3 2024
Neutral
GlobeNewsWire
●
6 months ago
Vincerx Pharma Reports First Quarter 2024 Financial Results and Provides Corporate Update
Vincerx continued to progress Phase 1 dose-escalation studies for VIP943, a potentially best-in-class anti-CD123 antibody-drug conjugate (ADC), and VIP236, a first-in-class small molecule-drug conjugate (SMDC)

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now
The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today